Skip to main content
[Preprint]. 2021 Jun 17:2021.06.14.21258567. [Version 1] doi: 10.1101/2021.06.14.21258567

Table 3.

Treatment-Emergent Adverse Events Occurring in ≥2% of Participants.*

Preferred Term — no. of participants (%) Placebo (N=1306) REGEN-COV 1200 mg SC (N=1311)

Covid-19 112 (8.6) 15 (1.1)
Asymptomatic Covid-19 108 (8.3) 54 (4.1)
Headache 46 (3.5) 24 (1.8)
Injection site reaction 19 (1.5) 55 (4.2)
*

Regardless of the SARS-CoV-2 serology status at baseline. SC denotes subcutaneous.